Vermilion Energy (VET) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -233.33%. A quarter ago, it was expected that this oil and natural gas explorer would post earnings of $0.17 per share when it actually produced earnings of $0.07, delivering a surprise of -58.82%.Over the last four quart ...

分组1 - TripAdvisor reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, and up from $0.39 per share a year ago, representing an earnings surprise of +9.52% [1] - The company posted revenues of $529 million for the quarter ended June 2025, which was slightly below the Zacks Consensus Estimate by 0.27%, but an increase from $497 million year-over-year [2] - TripAdvisor has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 11.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $572.28 million, and for the current fiscal year, it is $1.45 on revenues of $1.94 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Kemper (KMPR) came out with quarterly earnings of $1.3 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $1.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.47%. A quarter ago, it was expected that this insurance holding company would post earnings of $1.48 per share when it actually produced earnings of $1.65, delivering a surprise of +11.49%.Over the last four quarters, th ...

Group 1: Earnings Performance - California Resources Corporation (CRC) reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $0.91 per share, and up from $0.6 per share a year ago, representing an earnings surprise of +20.88% [1] - The company posted revenues of $978 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 21.84%, compared to year-ago revenues of $514 million [2] - Over the last four quarters, California Resources has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - California Resources shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the coming quarter is $1.06 on revenues of $845.76 million, and for the current fiscal year, it is $3.71 on revenues of $3.32 billion [7] - The company's earnings outlook and estimate revisions will be crucial for future stock performance, with a current Zacks Rank of 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Oil and Gas - Exploration and Production - United States industry is currently in the bottom 31% of over 250 Zacks industries, which may impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5]

Core Insights - Yum! Brands Inc reported second-quarter earnings of $1.44 per share, slightly below the Zacks Consensus Estimate of $1.45, and revenue of $1.93 billion, just under the expected $1.94 billion [1] - The company's underperformance was attributed to weak domestic results from KFC and Pizza Hut, which are facing significant competition [1] Stock Performance - Following the earnings report, Yum! Brands' stock declined by 3.1%, trading at $142.42, although it still maintains a 6.26% year-to-date gain [2] - Support at the $140 level has helped stabilize the stock since February [2] Analyst Sentiment - Analysts show caution towards Yum! Brands, with nine maintaining a "strong buy" rating and 18 a "hold" rating [3] - Options traders have exhibited increased bullish sentiment, with a call/put volume ratio of 1.85, higher than 96% of readings from the past year [3] Options Activity - Options volume is currently five times the typical intraday average, with the most active contract being the monthly 8/15 140-strike call [4]

Group 1 - The core viewpoint is that CICC has initiated coverage on Nantong Jiangshan Chemical Co., Ltd. with an "Outperform" rating [1] - The target price is set at 28.66 yuan, indicating a potential upside of 32% from the stock's latest price [1]

Core Insights - Axalta Coating Systems reported revenue of $1.31 billion for the quarter ended June 2025, a decrease of 3.4% year-over-year, with EPS at $0.64, up from $0.57 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $1.32 billion, resulting in a surprise of -1.33%, while the EPS exceeded the consensus estimate of $0.61 by 4.92% [1] Financial Performance - Total sales in Performance Coatings were $836 million, below the average estimate of $872.1 million, reflecting a year-over-year decline of 5.8% [4] - Total sales in Mobility Coatings reached $469 million, slightly above the average estimate of $463.08 million, marking a year-over-year increase of 1.1% [4] - Sales in Mobility Coatings for commercial vehicles were $107 million, compared to an estimate of $100.02 million, showing a decline of 2.7% year-over-year [4] - Sales in Performance Coatings for industrial applications were $322 million, below the average estimate of $327.45 million, representing a year-over-year decrease of 5.6% [4] - Sales in Mobility Coatings for light vehicles were $362 million, slightly below the estimate of $363.06 million, with a year-over-year increase of 2.3% [4] - Sales in Performance Coatings for refinish applications were $514 million, below the average estimate of $544.4 million, reflecting a year-over-year decline of 5.9% [4] - Adjusted EBIT for Mobility Coatings was $92 million, exceeding the estimate of $74.79 million [4] - Adjusted EBIT for Performance Coatings was $200 million, below the average estimate of $209.59 million [4] Market Performance - Axalta Coating Systems' shares have returned -5.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2][5] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, reliance solely on brokerage recommendations may not be advisable, as studies suggest they often fail to guide investors effectively towards stocks with high price appreciation potential [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, often resulting in a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is presented in whole numbers and is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics has declined by 1.4% over the past month to -$5.61, indicating growing pessimism among analysts regarding the company's earnings prospects [14][15] Group 3 - The recent change in the consensus estimate, along with other earnings-related factors, has led to a Zacks Rank of 4 (Sell) for CRISPR Therapeutics, suggesting caution despite the favorable ABR [15] - The ABR may not always reflect the most current information, while the Zacks Rank is updated more frequently to reflect changes in earnings estimates [13]

Core Viewpoint - RE/MAX reported a decline in revenue and earnings for the quarter ended June 2025, indicating potential challenges in financial performance compared to previous periods and market expectations [1][3]. Financial Performance - Revenue for the quarter was $72.75 million, down 7.3% year-over-year, and below the Zacks Consensus Estimate of $73.47 million by 0.98% [1]. - Earnings per share (EPS) were $0.39, a decrease from $0.41 in the same quarter last year, but exceeded the consensus estimate of $0.35 by 11.43% [1]. Key Metrics - Marketing Funds fees revenue was $18.27 million, slightly above the average estimate of $18 million, but down 8.8% year-over-year [4]. - Continuing franchise fees revenue was $28.99 million, below the average estimate of $29.32 million, reflecting a 4.4% decline year-over-year [4]. - Franchise sales and other revenue totaled $4.34 million, significantly lower than the $4.87 million average estimate, marking a 19.8% decrease year-over-year [4]. - Broker fees revenue was $13.45 million, slightly above the average estimate of $13.39 million, with a year-over-year decline of 7.4% [4]. - Annual dues revenue was $7.69 million, below the estimated $7.85 million, representing a 5.6% decrease compared to the previous year [4]. Stock Performance - Over the past month, RE/MAX shares returned +0.1%, underperforming the Zacks S&P 500 composite's +3.6% change [3]. - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3].

Core Viewpoint - The average brokerage recommendation (ABR) for Diebold Nixdorf, Incorporated (DBD) is 1.00, indicating a Strong Buy based on recommendations from three brokerage firms, all of which are Strong Buy [2][5] Brokerage Recommendation Trends - The current ABR of 1.00 is derived from three Strong Buy recommendations, representing 100% of all recommendations [2] - Despite the Strong Buy recommendation, reliance solely on brokerage recommendations may not be wise, as studies show limited success in guiding investors to stocks with the best price increase potential [5][10] Zacks Rank and Its Importance - Zacks Rank categorizes stocks into five groups, from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and is based on earnings estimate revisions, which correlate strongly with near-term stock price movements [8][11] - The Zacks Rank is distinct from ABR, as it is a quantitative model that reflects timely earnings estimate revisions, while ABR may not be up-to-date [9][13] Current Earnings Estimates for DBD - The Zacks Consensus Estimate for Diebold Nixdorf, Incorporated remains unchanged at $3.57 for the current year, indicating steady analyst views on the company's earnings prospects [14] - The unchanged consensus estimate has resulted in a Zacks Rank 3 (Hold) for Diebold Nixdorf, suggesting caution despite the Buy-equivalent ABR [15]